Microvascular and macrovascular complications of diabetes mellitus

American Journal of Pharmaceutical Education

Volumn 69, Issue 5, 2005, Pages

  King, Keecia D ^a,b   Jones, Jocelyn D ^a   Warthen, Jessica ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

Diabetes; Macrovascular; Microvascular

Indexed keywords

EID: 33645242536     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: 10.5688/aj690587     Document Type: Article

References (64)

1. Chronic Disease Overview. National Center for Chronic Disease Prevention and Health Promotion. Available at: http://www.cdc.gov/nccdphp/overview.htm. Accessed January 23, 2005.
2. National Diabetes Fact Sheet. National Center for Disease Prevention and Health Promotion. Available at: http://www.cdc.gov/diabetes/pubs/factsheet.htm. Accessed January 4, 2005.
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
5. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21:160-78.
6. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-68.
7. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2005;28:S37-42.
8. Edelman SV. Glycemic Control: The Future of Diabetes Management. Proceedings of the American Diabetes Association 61st Scientific Session. Philadelphia, PA. June 26, 2001. Available at: http://www.diabetes.org. Accessed October 24, 2005.
9. Setter SM, Campbell RK, Cahoon C. Biochemial Pathways of Microvascular Complication in Diabetes Mellitus. Ann Pharmacother. 2003;37:1858-66.
10. Hammes HP. Retinopathy: New Research, Unifying Concepts. Proceedings of the American Diabetes Association 64th Scientific Session. Orlando, FL. June 4-8, 2004. Available at: http://www.diabetes.org. Accessed October 24, 2005.
11. Kuroki T, Isshiki K, King G. Oxidative Stress: The Lead or Supporting Actor in the Pathogenesis of Diabetic Complications. J Am Soc Nephrol. 2003;14:S216-20.
12. Preventing Diabetes and Its Complications. National Center for Chronic Disease Prevention and Health Promotion. Available at: http://www.cdc.gov/nccdphp/pe_factsheets/pe_ddt.htm. Accessed January 23, 2005.
13. Spijkerman AM, Dekker JM. Microvascular Complications at Time of Diagnosis of Type 2 Diabetes Are Similar Among Diabetic Patients Detected by Targeted Screening and Patients Newly Diagnosed in General Practice. Diabetes Care. 2003;26:2604-8.
14. Chau DL, Shumaker N, et al. Complications of Type 2 Diabetes in the Elderly. Available at: http://www.geriatrictimes.com/g030411.html. Accessed January 23, 2005.
15. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993;16:642-52.
16. Zimmerman R. Microvascular Complications of Diabetes. Available at: http://www.clevelandclinicmeded.com/diseasemanagement/endocrinology/ microvascular/microvascular1.htm. Accessed October 24, 2005.
17. Diabetes and nephropathy (kidney complications). American Diabetes Association. Available at: http://diabetes.org/diabetes-statistics/kidney-disease.jsp. Accessed January 25, 2005.
18. American Diabetes Association. Clinical Practice Recommendations 2003. Diabetes Care. 2003;26(Suppl 1):S94-7.
19. Huynh P, White J. Screening for renal disease in patients with type 2 diabetes mellitus. US Pharmacist. Available at: http://www.uspharmacist.com/index.asp?show=article&page=8_1172.htm#T1. Accessed January 26, 2005.
20. American Diabetes Association. Nephropathy in Diabetes. Diabetes Care. 2004;27:S79-83.
21. Young B. Pharmacologic Treatment of Diabetic Nephropathy. North Am Pharmacother. 2004;2:50-1.
22. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE Study and MICRO-HOPE substudy. Lancet. 2000;355:253-9.
23. Martins D, Norris K. Combating diabetic nephropathy with drug therapy. Curr Diabetes Rep. 2001;1:148-56.
24. Brenner BM, Cooper ME, Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
25. Boulton A. Management of diabetic peripheral neuropathy. Clinical Diabetes. 2005;23:9-15.
26. Vinik A. Neuropathy: new concepts in evaluation and treatment. South Med J. 2002;95:21-3.
27. Russell D, Stading J. Diabetic Peripheral Neuropathy: Minimizing and Treating Its Pain. Available at: http://www.uspharmacist.com/index.asp?show=article&page=8_996.htm. Accessed January 28, 2005.
28. Duby JJ, Campbell RK. Diabetic neuropathy: an intensive review. Am J Health-Syst Pharm. 2004;61:160-76.
29. Grief CJ, Conn DK, Reekam RV. The treatment of chronic pain with antidepressants in older adults. J Geriatric Care. 2002;1:255-63.
30. Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2004.
31. Hollis I. Duloxetine (Cymbalta). Pharmacother Update. 2004;7: 1-2.
32. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized Double-blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain. Arch Intern Med. 1999;159:1931-7.
33. Pfizer Pharmaceuticals. Lyrica (Pregabalin) - New Gabapentinoid with Wide Clinical Application. Available at: http://www.drugdevelopment-technology.com/project_printable.asp?ProjectID=2682. Accessed January 28, 2005.
34. Gimbel JS, MD, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology. 2003;60:927-34.
35. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842-6.
36. Duby J, Campbell RK. Treatment of painful diabetic neuropathy: a review of the current evidence. US Pharm. 2004;11HS-10-HS-24.
37. Diabetes: Disabling, Deadly and on the Rise. National Center for Chronic Disease Prevention and Health Promotion. Available at: http://www.cdc.gov/nccdphp/aag/aag_ddt.htm. Accessed January 30, 2005.
38. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in Diabetes. Diabetes Care. 2004;27:84S-7S.
39. Eye Foundation of Kansas City. Diabetic Retinopathy. Available at: http://www.umkc-efkc.org/diseases/diabetes/diabetes.htm. Accessed January 30, 2005.
40. Diabetic Retinopathy: Control of Systemic Factors Preserves Vision. Postgraduate Medicine. Available at: http://www.postgradmed.com/issues/2004/07_04/colucciello.htm. Accessed January 30, 2005.
41. Maitra A, Abbas AK. The endocrine system. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran: Pathologic Basis of Disease, 7th ed. Philadelphia, Pa: Elseiver; 2005:1155-205.
42. National Diabetes Fact Sheet. American Diabetes Association. Available at: http://www.diabetes.org/diabetes-statistics/national-diabetes-fact-sheet.jsp. Accessed January 30, 2005.
43. Haffner SM. Reducing Cardiovascular Disease Risk Across the Continuum of Glucose Tolerance. Available at: http://www.medscape.com/viewprogram/3517_pnt. Accessed January 30, 2005.
44. American Diabetes Association Clinical Recommendations. Diabetes Care. 2005;28:S4-S36.
45. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-52.
46. Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
47. Welty TE. Cerebrovascular. In: Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, eds. Applied Therapeutics: The Clinical Use of Drugs, 7th ed. Baltimore, Md: Lippincott Williams & Wilkins; 2001:53-1-53-25.
48. Kothari R, Barsan WG. Stroke. In: Marx JA, Hockberger RS, Walls RN, eds. Rosen's Emergency Medicine: Concepts and Clinical Practice, 5th ed. St Louis, Ms: Mosby Inc.; 2002: 1433-45.
49. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic strokeLancet. 1997;349:1569.
50. Chinese Acute Stroke Trial Collaborative Group: CAST: Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349:1641.
51. Multicenter Acute Stroke Trial - Italy (MAST-I) Group: Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet. 1995;346:1509.
52. Creager MA, Libby P. Peripheral artery disease. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardiovascular Medicine, 6th ed. Philadelphia, Pa: WB Saunders Company; 2001:1027-8.
53. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997;96:44-9.
54. Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study. JAMA. 1972;221:661-6.
55. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
56. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 1994;308:159-68.
57. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicenter Study. J Intern Med. 1990;227:301-8.
58. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39.
59. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med. 1990;113:135-46.
60. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vascular Surg. 1998;27:267-74.
61. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med. 1999; 159:2041-50.
62. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-75.
63. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
64. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and the risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703-13.